AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
FOLD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. Both the profitability and the financial health of FOLD get a neutral evaluation. Nothing too spectacular is happening here. FOLD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
FOLD had negative earnings in the past year.
FOLD had a positive operating cash flow in the past year.
FOLD had negative earnings in each of the past 5 years.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of FOLD (-3.72%) is better than 88.21% of its industry peers.
With an excellent Return On Equity value of -15.18%, FOLD belongs to the best of the industry, outperforming 87.32% of the companies in the same industry.
With an excellent Return On Invested Capital value of 5.93%, FOLD belongs to the best of the industry, outperforming 93.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROIC | 5.93% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 8.80%, FOLD belongs to the best of the industry, outperforming 93.57% of the companies in the same industry.
FOLD has a Gross Margin of 90.60%. This is amongst the best in the industry. FOLD outperforms 92.68% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, FOLD has more shares outstanding
FOLD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FOLD has been reduced compared to a year ago.
2.2 Solvency
FOLD has an Altman-Z score of -1.54. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
FOLD has a Altman-Z score of -1.54. This is comparable to the rest of the industry: FOLD outperforms 57.86% of its industry peers.
FOLD has a debt to FCF ratio of 242.98. This is a negative value and a sign of low solvency as FOLD would need 242.98 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 242.98, FOLD belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
FOLD has a Debt/Equity ratio of 2.02. This is a high value indicating a heavy dependency on external financing.
FOLD has a Debt to Equity ratio of 2.02. This is amonst the worse of the industry: FOLD underperforms 81.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Altman-Z | -1.54 |
ROIC/WACC0.56
WACC10.59%
2.3 Liquidity
A Current Ratio of 3.34 indicates that FOLD has no problem at all paying its short term obligations.
The Current ratio of FOLD (3.34) is worse than 60.71% of its industry peers.
A Quick Ratio of 2.47 indicates that FOLD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.47, FOLD is not doing good in the industry: 68.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.63%, which is quite impressive.
Looking at the last year, FOLD shows a very strong growth in Revenue. The Revenue has grown by 28.26%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 77.43% on average per year.
FOLD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.68% yearly.
EPS Next Y57.82%
EPS Next 2Y86.03%
EPS Next 3Y81.37%
EPS Next 5Y77.43%
Revenue Next Year17.8%
Revenue Next 2Y20.62%
Revenue Next 3Y21.59%
Revenue Next 5Y20.68%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 23.09, the valuation of FOLD can be described as rather expensive.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 91.61% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of FOLD to the average of the S&P500 Index (22.15), we can say FOLD is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.09 |
4.2 Price Multiples
FOLD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. FOLD is cheaper than 92.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, FOLD is valued cheaper than 91.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1162.4 | ||
| EV/EBITDA | 35.41 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 81.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.03%
EPS Next 3Y81.37%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.07
-0.14 (-2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.04%
Inst Owner Change4.3%
Ins Owners0.7%
Ins Owner Change12.82%
Market Cap1.87B
Analysts82.22
Price Target16.12 (165.57%)
Short Float %6.58%
Short Ratio4.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)106.71%
Min EPS beat(2)-26.06%
Max EPS beat(2)239.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)-0.84%
Revenue beat(4)2
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)2.52%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)6
Avg Revenue beat(12)-1.43%
Revenue beat(16)8
Avg Revenue beat(16)-1.23%
PT rev (1m)-5.95%
PT rev (3m)-7.55%
EPS NQ rev (1m)-962.32%
EPS NQ rev (3m)-608.56%
EPS NY rev (1m)-331.04%
EPS NY rev (3m)-165.05%
Revenue NQ rev (1m)-1.68%
Revenue NQ rev (3m)-3.25%
Revenue NY rev (1m)-1.66%
Revenue NY rev (3m)-2.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.09 | ||
| P/S | 3.44 | ||
| P/FCF | 1162.4 | ||
| P/OCF | 524.74 | ||
| P/B | 9.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.41 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.26
Fwd EY4.33%
FCF(TTM)0.01
FCFY0.09%
OCF(TTM)0.01
OCFY0.19%
SpS1.76
BVpS0.63
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.72% | ||
| ROE | -15.18% | ||
| ROCE | 7.5% | ||
| ROIC | 5.93% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 21.92% | ||
| OM | 8.8% | ||
| PM (TTM) | N/A | ||
| GM | 90.6% | ||
| FCFM | 0.3% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.02 | ||
| Debt/FCF | 242.98 | ||
| Debt/EBITDA | 6.97 | ||
| Cap/Depr | 23.74% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 6.36% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.34 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | -1.54 |
F-Score7
WACC10.59%
ROIC/WACC0.56
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y57.82%
EPS Next 2Y86.03%
EPS Next 3Y81.37%
EPS Next 5Y77.43%
Revenue 1Y (TTM)28.26%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%13.45%
Revenue Next Year17.8%
Revenue Next 2Y20.62%
Revenue Next 3Y21.59%
Revenue Next 5Y20.68%
EBIT growth 1Y179.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.34%
EBIT Next 3Y110.27%
EBIT Next 5YN/A
FCF growth 1Y101.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.82%
OCF growth 3YN/A
OCF growth 5YN/A